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Abstract: Copper (Cu) transporter 2 (Ctr2) is a transmembrane protein that transports Cu 
across cell membranes and increases cytosolic Cu levels. Experiments using cell lines have 
suggested that Ctr2 expression is regulated by Cu status. The importance of changes in 
Ctr2 expression is underscored by recent studies demonstrating that lower Ctr2 content in 
cells increases the cellular uptake of platinum-containing cancer drugs and toxicity to the 
drugs. In this study, we examined whether Ctr2 expression is altered by a nutritional Cu 
deficiency  in  vivo.  Ctr2  mRNA  and  protein  in  liver  and  heart  from  rats  fed  a  normal  
(Cu-N), moderately deficient (Cu-M) or deficient (Cu-D) Cu diet was measured. Rats fed 
the Cu-deficient diets showed a dose-dependent decrease in liver Ctr2 protein compared to 
Cu-N rats. Ctr2 protein was 42% and 85% lower in Cu-M and Cu-D rats, respectively. 
Liver Ctr2 mRNA was 50% lower in Cu-D rats and unaffected in Cu-M rats. In heart, Ctr2 
protein was only lower in Cu-D rats (46% lower). These data show that Cu deficiency 
decreases Ctr2 content in vivo.  
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1. Introduction  
Copper (Cu) transporter 1 (Ctr1) and Cu transporter 2 (Ctr2) are structurally similar Cu transporters 
that transfer Cu across cell membranes and increase Cu levels in the cytosol of cells. Ctr1 is a major 
Cu  importer  that  mediates  high  affinity  Cu  uptake  at  the  plasma  membrane  in  the  form  of  a 
homotrimer [1–4]. Less is known about the function and structure of Ctr2; however, Ctr2 functions as 
a homomultimer similar to Ctr1 [5,6]. In the yeast Saccharomyces cerevisiae, Ctr2 localizes to the 
vacuole and transports Cu from the vacuole to the cytosol [6]. A similar role has been described for the 
Schizosaccharomyces pombe ortholog Ctr6 [7]. In mammalian cells, Ctr2 has been localized in late 
endosomes  and  lysosomes  [5]  and  the  cell  nucleus  [8].  Our  lab  has  shown  that  in  African  green 
monkey kidney COS-7 cells, Ctr2 localizes predominantly to large cytoplasmic vesicles with a small 
proportion distributed at the cell surface where it transports Cu into cells [9].  
It is now well-established that proteins involved in the trafficking of Cu also play an important role 
in the metabolism of commonly used platinum-based chemotherapeutic drugs such as cisplatin and 
carboplatin [10–18]. Mouse embryonic fibroblast (MEF) cells lacking Ctr1 showed a marked reduction 
in cisplatin accumulation and increased resistance to its cytotoxic effects [12]. In contrast to Ctr1, 
lower  levels  of  Ctr2  increases  the  cellular  uptake  of  platinum-based  chemotherapeutic  drugs  and 
toxicity  to  the  drugs  [16,17].  Knocking  down  Ctr2  in  MEF  cells  increased  the  accumulation  of 
cisplatin by 2–3-fold, which was associated with increased cytotoxicity to cisplatin [16]. Furthermore, 
an evaluation of several human ovarian carcinoma cell lines revealed that Ctr2 content was inversely 
correlated with sensitivity to cisplatin [16].  
A recent study by Blair et al. has suggested that lower Ctr2 content in cells increases the uptake of 
cisplatin by increasing the rate of macropinocytosis through activation of Rac1 and cdc42 [17]. In that 
study, Blair et al. also showed that, in mice, tumors formed from cells in which Ctr2 was knocked 
down using a lentiviral vector expressing a shRNAi directed against Ctr2 grew significantly slower 
compared  to  tumors  formed  from  the  parental  cell  line  [17].  Tumors  from  Ctr2  knockdown  cells 
showed increased frequency of apoptotic cells and decreased vascular density.  
Cellular  Cu  homeostasis  is  maintained  by  regulating  the  uptake,  intracellular  distribution  and 
elimination  of  Cu  via  the  activity  of  Cu  transporters  and  chaperones  [19].  Changes  in  cellular 
expression of Cu transporters and chaperones in response to changes in Cu availability are likely 
regulatory mechanisms that have evolved to help cells cope with sub- or supra-optimal levels of Cu. 
We and others have shown that Cu promotes the degradation of Cu chaperone for Cu/Zn superoxide 
dismutase  (CCS)  [20,21].  Cu  binding  to  the  C-terminal  CXC  (C,  cysteine;  X,  any  amino  acid)  
Cu-binding  motif  decreases  CCS  stability  and  increases  the  rate  of  degradation  by  the  26  S  
proteasome [20,21]. Induction of Cu deficiency in animals by feeding a Cu-deficient diet increases 
CCS content in tissues and therefore CCS is a good indicator of Cu deficiency in vivo [20,22–25]. 
Elevated CCS under conditions of Cu deficiency may increase the efficiency of Cu delivery to its 
target enzyme Cu/Zn superoxide dismutase (SOD1) and preserve its activity in the cell. Expression of 
Ctr1 is also regulated by Cu availability. Addition of supplemental Cu to certain cell types induces the 
internalization of Ctr1 from the plasma membrane and degradation of the protein [26]. Ctr1 content is 
also increased in tissues of Cu-deficient mice [27,28]. Changes in Ctr1 expression may be a regulatory 
mechanism to reduce cellular Cu uptake when Cu is in excess and increase uptake when Cu is scarce.  Int. J. Mol. Sci. 2010, 11                       
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In  vitro  experiments  using  cell  lines  have  suggested  that  Ctr2  expression  is  regulated  by  Cu  
status [8]. Ctr2 mRNA and protein in human ovarian carcinoma 2008 and MEF cells increased when 
cells were cultured in medium supplemented with a high concentration of Cu (i.e., 200 mol/L) [8]. 
Conversely, Ctr2 mRNA and protein were decreased in cells cultured in medium supplemented with 
the Cu chelator bathocuproine disulfonate [8]. In cells treated with cyclohexamide to block protein 
synthesis, Ctr2 protein showed an extended half-life when incubated in the presence of supplemental 
Cu,  suggesting  that  Cu  status  regulates  Ctr2  expression,  at  least  in  part,  by  a  post-translational 
mechanism [8]. Interestingly, post-transcriptional regulation of Ctr2 in response to Cu deficiency or 
excess appears to be dependent on the Cu chaperone ATOX1 [8].  
Given  the  in  vitro  evidence  suggesting  that  Cu  status  determines  Ctr2  content  in  cells,  we 
investigated  whether  Cu  deficiency  affects  Ctr2  expression  in  vivo.  In  this  study,  we  show  that  
Ctr2 content is decreased in a dose-dependent manner in liver and heart of rats with a nutritional  
Cu deficiency.  
2. Results and Discussion 
In this study we examined whether Ctr2 mRNA and protein are altered in response to Cu deficiency 
in liver and heart of rats. Rats were fed a Cu-normal (Cu-N), moderately Cu-deficient (Cu-M) or  
Cu-deficient (Cu-D) diet. We have previously characterized the Cu status of these rats [22]. Rats fed 
the  Cu-restricted  diets  showed  changes  in  established  biomarkers  of  Cu  deficiency.  Liver  and 
erythrocytes had decreased activity of the Cu-dependent enzyme SOD1 and increased expression of its 
chaperone CCS indicating that the rats had depressed Cu status [22]. Notably, CCS content in liver and 
erythrocytes  of  Cu-D  rats  was  higher  compared  to  Cu-M  rats  indicating  more  pronounced  Cu 
deficiency in Cu-D rats [22].  
Ctr2 content in liver and heart extracts was measured by Western blot using a custom made Ctr2 
antibody. Our group and others have previously used this antibody to detect transiently overexpressed 
Ctr2 and endogenous Ctr2 in rat tissues and cell lines from different species [8,9,16,17]. Our previous 
work showed that our Ctr2 antibody detected a predominant band of 70 kDa in size in COS-7 cells 
and rat tissues, including liver and heart [9]. Because the primary amino acid sequence of Ctr2 predicts 
a protein of 17 kDa, it was important to establish that the 70 kDa band detected represents Ctr2. We 
previously  showed  that  in  COS-7  cells,  siRNAs  targeted  to  different  regions  of  the  Ctr2  mRNA 
sequence were able to knockdown the 70 kDa band detected with our Ctr2 antibody confirming that 
the 70 kDa band represents Ctr2 [9]. Moreover, Blair et al. have also detected Ctr2 as a 70 kDa band 
in MEF cells [17]. However, in contrast with our data they also detected a band of 17 kDa of about 
equal intensity. The intensities of both the 70 and 17 kDa bands were strongly depressed in cells 
infected with lentivirus expressing a shRNAi targeting the mouse Ctr2 mRNA confirming that both 
bands represent Ctr2. The 17 kDa band represents the Ctr2 monomer as this is the predicted size based 
on the amino acid sequence of Ctr2. Given that Ctr2 functions as a homomultimer, the 70 kDa band 
likely represents a mutimeric form of Ctr2. It is unclear why we did not detect the 17 kDa band in 
COS-7  cells  and  rat  tissues,  but  it  may  be  explained  by  species  differences  or  differences  in  the 
preparation  of  the  protein  extracts  or  Western  blotting  procedure  that  affects  the  mutimerization  
state of Ctr2.  Int. J. Mol. Sci. 2010, 11                       
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Consistent  with  our  previously  published  data,  Ctr2  was  detected  as  a  single  strong  band  of 
70 kDa in size in liver and heart extracts. Ctr2 protein showed a dose-dependent decrease in liver of 
rats fed diets low in Cu (Figure 1A). In comparison to Cu-N rats, Ctr2 was 42% lower in Cu-M rats 
and showed a marked 85% reduction in Cu-D rats (Figure 1A). A repetition of the experiment using 
three different rats from each diet group gave similar results (data not shown). Further, all Cu-D rats 
from  this  study  showed  a  marked  reduction  in  liver  Ctr2  protein  content  (data  not  shown).  The 
observed magnitude of change in Ctr2 is significant considering that a modest 33–55% reduction in 
Ctr2  protein  in  MEF  cells  in  knockdown  experiments  resulted  in  a  2–3-fold  increase  in  the 
accumulation of the platinum-based chemotherapeutic drug cisplatin, which was associated with a 
large increase in toxicity of the drug [16].  
Figure 1. Ctr2 expression in liver of Cu-deficient rats. (A) Representative Western blot of 
liver extracts from Cu-N, Cu-M or Cu-D rats probed with an antibody against Ctr2. The 
membrane was stripped and probed with an antibody against -tubulin. Intensities of the 
Ctr2 bands relative to -tubulin are depicted graphically (top panel); (B) QPCR analyses of 
Ctr2 mRNA expression in liver. Ctr2 mRNA abundance is presented relative to GAPDH 
mRNA abundance. For Cu-N rats, Ctr2 expression was arbitrarily set to 1. Values are 
means ±  SEM, n = 3 (A) or n = 6 (B).  Different from Cu-N rats, P < 0.05.  
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Whereas  Ctr2  protein  was  markedly  lower  in  liver  of  Cu-restricted  rats,  Ctr2  mRNA  was  less 
affected.  Liver  Ctr2  mRNA  was  not  significantly  lower  in  Cu-M  rats  compared  to  Cu-N  rats 
(Figure 1B). In Cu-D rats, Ctr2 mRNA was 50% lower compared to Cu-N rats (Figure 1B). The larger 
magnitude of decrease of Ctr2 protein compared to mRNA indicates that both transcriptional  and  
post-transcriptional mechanisms regulate Ctr2 expression in response to decreased Cu status in rat 
liver. These results are in agreement with the cell culture experiments of Blair et al. demonstrating 
both transcriptional and post-translational regulation of Ctr2 expression in response to addition of high 
amounts of Cu or a Cu chelator to the cell culture medium [8]. The decrease in Ctr2 protein in the 
absence of a significant decrease in Ctr2 mRNA in Cu-M rats with a milder Cu deficiency suggests 
that the post-transcriptional mechanism for Ctr2 regulation is more sensitive to moderate reductions in 
Cu status  compared to  the transcriptional mechanism. Thus, the post-transcriptional mechanism is 
likely the more biologically relevant mechanism for Ctr2 regulation in response to Cu deficiency.  
It is noteworthy to mention that human ovarian carcinoma 2008 cells cultured in the presence of a  
Cu  chelator  showed  a  modest  29%  decrease  in  Ctr2  mRNA,  but  a  much  larger  90%  decrease  in  
Ctr2 protein [8]. 
Ctr2 protein in heart of Cu-M rats was not significantly lower compared to Cu-N rats (1.00 ±  0.12 
vs. 0.86 ±  0.30, P > 0.05, n = 4). However, heart Ctr2 protein was lower in Cu-D rats (1.00 ±  0.03 vs. 
0.54 ±  0.12, P < 0.05, n = 4). Compared to liver Ctr2, the magnitude of decrease in heart Ctr2 was 
smaller indicating that Ctr2 expression in liver is more sensitive to decreases in Cu status in rats.  
It is presently not understood why Ctr2 content is reduced in response to Cu deficiency. It has been 
demonstrated that knocking down Ctr2 increases Cu uptake in MEF cells expressing Ctr1, but not in an 
isogenic cell line lacking Ctr1 [16]. These data suggest that a decrease in Ctr2 increases cellular Cu 
uptake directly by Ctr1 or by a Ctr1-dependent mechanism. It is possible that lower Ctr2 content in 
cells may act as a signal of low intracellular Cu levels that stimulates Cu uptake by the cell.  
3. Experimental Section  
3.1. Animals and Test Diets  
The  experimental  animal  protocol  and  test  diets  have  been  described  elsewhere  [22].  Briefly, 
weanling (21-day-old) male Wistar rats (Charles River Canada, St. Constant, Canada) were randomly 
assigned to 1 of 3 diet groups (n = 10/group). Test diets were nutritionally complete but contained 
different amounts of Cu. Cu-normal (Cu-N), moderately Cu-deficient (Cu-M) or Cu-deficient (Cu-D) 
diets contained 5.3 ±  0.06, 0.84 ±  0.03 and 0.34 ±  0.01 mg of Cu/kg diet, respectively. After 6 weeks 
of feeding the diets, rats were killed and tissues were collected and stored at −80 C until analysis. The 
experimental protocol was approved by the Animal Care Committee of the Health Products and Food 
Branch of Health Canada.  
3.2. Tissue Extracts and Western Blotting 
Preparation  of  tissue  extracts  and  Western  blotting  procedure  were  performed  essentially  as 
described  [9].  Liver  and  heart  were  homogenized  in  0.5%  Triton  X-100  supplemented  with  a  
protease inhibitor cocktail (Roche Diagnostics, Laval, Canada). Supernatant was recovered following Int. J. Mol. Sci. 2010, 11                       
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centrifugation and total liver (40 g) or heart (20 g) proteins were separated over 8–16% Tris-Glycine 
gradient  gels  (Invitrogen,  Burlington,  Canada).  Proteins  were  electroblotted  onto  nitrocellulose 
membranes. Membranes were incubated with a primary antibody against Ctr2 that we have described 
previously [9] or an antibody against -tubulin (H-235, Santa Cruz Biotechnology, Santa Cruz, CA) 
for 3 h at room temperature at a concentration of 2 g/mL or 0.67 g/mL, respectively. Following 
incubation with an anti-rabbit horseradish peroxidase-conjugated secondary antibody, proteins were 
detected by enhanced chemiluminescence and exposure to film. Film was scanned and band intensities 
were determined using Scion Image software (Scion Corporation, Frederick, MD).  
3.3. Quantitative PCR (QPCR) 
Total RNA was extracted from liver using the RNeasy
® kit (QIAGEN, Mississauga, Canada) and 
cDNA was generated using an oligo(dT) primer. QPCR was performed with an Mx4000 Multiplex 
Quantitative PCR System (Stratagene, La Jolla, CA) using the Brilliant SYBR Green QPCR reagent kit 
(Stratagene) and primer sets specific for Ctr2 (forward primer, 5'-AACTTCAGACAATAGGACCCGCCT-3'; 
reverse  primer,  5'-TAGGACATGACAGCCAGCATCACA-3')  or  glyceraldehyde-3-phosphate 
dehydrogenase  (GAPDH)  (forward  primer,  5'-TCAAGAAGGTGGTGAAGCAGCC-3';  reverse 
primer, 5'-GCATCAAACGTGGAAGAATGGG-3'). Relative mRNA levels were determined using the 
standard curve method.  
3.4. Statistical Analyses 
Statistical analyses were performed using Statistica 8 software (StatSoft, Tulsa, OK). A t-test was 
used for comparison of means of 2 groups and an ANOVA test followed by a Dunnett test was used to 
compare means to a control group. Differences were considered significant at P < 0.05. Results were 
expressed as means ±  SEM.  
4. Conclusions  
In this study, we have demonstrated that a nutritional Cu deficiency decreases Ctr2 content in liver 
and heart of rats. These results add biological relevance to recently published cell culture experiments 
suggesting that Ctr2 expression is regulated by Cu status [8,17]. Extending these in vitro observations 
to animals is particularly significant given the recent discoveries that lower Ctr2 content increases 
cellular  uptake of commonly  used  platinum-based chemotherapeutic drugs,  increases sensitivity  to 
these drugs and slows tumor growth [16,17]. Given that Cu deficiency induces a number of adverse 
effects including anemia and impaired immune function [29–35], strategies aimed at lowering tumor 
cell Ctr2 levels by targeted reduction of Cu in tumor cells would be a better approach as opposed to 
depressing whole-body Cu status. Recently, nanoparticles have been engineered with the capability of 
targeted delivery of cisplatin to prostate cancer cells [36]. A similar approach could be envisioned for 
delivery of Cu-chelating drugs to cancer cells. With an efficient targeted delivery system, whole-body 
Cu status and Cu-dependent physiological processes would be expected to be minimally affected.  
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